-

Thermo Scientific Centrios HX Offers Precise Circuit Edit Solution for Fast Prototyping

Advanced semiconductor circuit edit system enables customers to quickly resolve preproduction design flaws and maintain device integrity and function

HILLSBORO, Ore.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific Centrios HX Circuit Edit System. This state-of-the-art circuit edit solution allows semiconductor manufacturers to optimize success rates with high resolution imaging and precise editing of today’s leading-edge devices.

As semiconductor devices become more complex, higher precision circuit edit tools are required to optimize product functionality and deliver prototypes to keep projects on track. Compared to other commercially available solutions, the Centrios HX with its new Celta FIB column offers the next level of improved resolution, beam current and landing energy for intricate circuit modification without adversely affecting circuit performance or integrity. This innovation allows semiconductor manufacturers to achieve faster time-to-market, while minimizing mask related development costs.

“With each semiconductor advancement, FIB circuit editing continues to grow in strategic importance as our customers design innovative technologies and bring them to market,” said Mohan Iyer, vice president and general manager of semiconductor at Thermo Fisher. “Next-generation logic devices, with buried power rails effectively blocking access to the active circuit area, will introduce new challenges. Engineered to support our customers in addressing the semiconductor industry’s evolving circuit edit requirements, the Centrios HX enables the ability to open windows in blocking metals for advanced editing and fault localization.”

The Centrios HX is designed to deliver precision and performance while maintaining device integrity and functionality. The new system enables engineers to:

  • Resolve fine features during circuit editing with up to 2.5 nanometer resolution at 250 femtoamperes (fA) with 30 kilovolts (kV).
  • Obtain highly consistent deposition and etching with the Thermo Scientific MultiChem Gas Delivery System.
  • Create open windows without circuit damage with operation at 5 kV.
  • Perform complicated edits with a patterning engine that offers a high degree of scan control.

For more information about the Thermo Scientific Centrios HX Advanced Circuit Edit System, visit: https://ter.li/dngibu. To register for the product launch webinar on March 1, 2022, visit: https://ter.li/obd119.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:
Brianna Radicioni
Thermo Fisher Scientific
+1 617-390-3924
brianna.radicioni@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media:
Brianna Radicioni
Thermo Fisher Scientific
+1 617-390-3924
brianna.radicioni@thermofisher.com

More News From Thermo Fisher

Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing....

Thermo Fisher Scientific Collaborates with The Michael J. Fox Foundation to Advance Proteomics-Enabled Parkinson’s Precision Medicine

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the completion of Olink Explore HT proteomic analysis of approximately 5,500 research samples from The Michael J. Fox Foundation’s (MJFF) landmark study, the Parkinson’s Precision Medicine Initiative (PPMI). The resulting data are now in PPMI’s data repository, where they are available to the global research community. The project creates a large-scale proteomics resource designe...

Thermo Fisher Scientific Presents End-to-End Diagnostic and Lab Solutions Addressing Unmet Clinical Needs at ADLM 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase its latest diagnostic innovations, recent regulatory milestones and expanded capabilities at the Association for Diagnostics & Laboratory Medicine Conference (ADLM), July 26-30, 2026, in Anaheim, Calif. Spanning specialty diagnostics, quality management and the full diagnostic continuum, Thermo Fisher’s presence at ADLM 2026 reflects its ongoing commitment to addressing unmet clinic...
Back to Newsroom